Metastasis Clinical Trial
Official title:
Cemiplimab Treatment in Patients With Locally Advanced and Metastatic Secondary Angiosarcomas
Verified date | April 2021 |
Source | Radboud University Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Secondary angiosarcomas are aggressive mesenchymal tumors with a poor prognosis and limited therapeutic options. Recent studies conducted in patients with cutaneous squamous-cell carcinoma provide evidence that cemiplimab has the potential to be an effective treatment also for patients with secondary angiosarcomas. The purpose of this study is to evaluate the overall response rate after 24 weeks of cemiplimab treatment in patients with locally advanced or metastatic secondary angiosarcomas. The investigators hypothesis is that cemiplimab could be an effective treatment for patients diagnosed with locally advanced and metastatic secondary angiosarcomas.
Status | Recruiting |
Enrollment | 18 |
Est. completion date | October 2025 |
Est. primary completion date | July 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Adult patient aged = 18 years. 2. Signed written informed consent. 3. Histologically confirmed diagnosis of progressive unresectable locally advanced or metastatic secondary angiosarcoma. 4. Patients in the first line of systemic treatment unfit for chemotherapy and patients in advanced lines of systemic treatment. 5. Measurable disease per RECIST 1.1 or per physical examination / daylight photography (WHO Offset Publication No. 48) as determined by the investigator. 6. Tumour tissue material available (archival or recent tumour biopsy). 7. WHO ECOG 0-2. 8. Hepatic function: 1. Total bilirubin = 1.5 x ULN (if liver metastases: = 3 x ULN). 2. Transaminases = 3 x ULN (if liver metastases: = 5 x ULN). 3. Patients with Gilbert's Disease and total bilirubin up to 3x ULN may be eligible after communication with and approval from the medical monitor 4. Alkaline phosphatase = 2.5 x ULN (if liver OR bone metastases =5 x ULN). 9. Renal function: serum creatinine = 2 x ULN or estimated CrCl > 30 mL/min. 10. Creatine phosphokinase (CPK) (also known as CK [creatine kinase]) elevation = grade 2 11. Bone marrow function: 1. Hemoglobulin = 9.0 g/dL. 2. ANC = 1.5 x 109/L. 3. Platelet count = 75 x 109/L. 12. Expected life expectancy of at least 3 months as judged by the investigator. Exclusion Criteria: 1. Ongoing or recent (within 5 years) evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments, which may suggest risk for irAEs. The following are not exclusionary: vitiligo, childhood asthma that has resolved, type 1 Diabetes mellitus, residual hypothyroidism that required only hormone therapy, or psoriasis that does not require systematic treatment. 2. Prior treatment with immune checkpoint inhibitors. 3. Continuous immunosuppressive corticosteroid treatment (doses > 10 mg prednisone daily or equivalent) within 4 weeks prior to the first dose of cemiplimab. Note: patients who require a brief course of steroids (e.g. as prophylaxis for imaging studies) are not excluded. 4. Active uncontrolled infection requiring therapy, including infection with HIV, active infection with HBV or HCV. 5. History of pneumonitis within the last 5 years. 6. Untreated brain metastasis(es) that may be considered active. a. Note in clarification: Patients with previously treated brain metastases may participate provided that the lesion(s) is (are) stable (without evidence of progression for at least 6 weeks on imaging obtained in the screening period), and there is no evidence of new or enlarging brain metastases, and the patients do not require any immunosuppressive doses of systemic corticosteroids for management of brain metastasis(es) within 28 days of the first dose of cemiplimab. 7. Patients with allergy or hypersensitivity to cemiplimab or to any of the excipients must be excluded. Specifically, because of the presence of trace components in cemiplimab, patients with allergy or hypersensitivity to doxycycline or tetracycline are excluded. 8. History of documented allergic reactions or acute hypersensitivity reaction attributed to antibody treatments 9. Patients with a history of solid organ transplant (patients with prior corneal transplants may be allowed to enroll after discussion with and approval from the medical monitor). 10. Any anticancer treatment other than radiation therapy (chemotherapy, targeted systemic therapy, imiquimod, photodynamic therapy), investigational or standard of care, within 30 days of the initial administration of cemiplimab or planned to occur during the study period 11. Receipt of live vaccines (including attenuated) within 30 days of first study treatment 12. Prior use of PI3K-D inhibitors 13. Women of childbearing potential (WOCBP)*, or sexually active men, who are unwilling to practice highly effective contraception prior to the initial dose/start of the first treatment prior to the start of the first treatment, during the study, and for at least 6 months after the last dose. 14. Breastfeeding 15. Positive serum pregnancy test (a false positive pregnancy test, if demonstrated by serial measurements and negative ultrasound, will not be exclusionary, upon communication with and approval from the medical monitor) 16. Any other condition that might interfere with experimental treatment and the study procedures as judged by the investigator. |
Country | Name | City | State |
---|---|---|---|
Netherlands | RadboudUMC | Nijmegen |
Lead Sponsor | Collaborator |
---|---|
Radboud University Medical Center | Genzyme Europe B.V. |
Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Overall Response Rate (ORR) after 24 weeks of cemiplimab | To evaluate the overall response rate (ORR) after 24 weeks of cemiplimab in secondary angiosarcomas, according to Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 or daylight photography as per WHO Offset Publication No. 48. | From the date of study inclusion until 24 weeks after inclusion. Interim analysis after 13 patients | |
Secondary | Best Overall Response Rate | To establish the best ORR of patients with secondary angiosarcomas receiving cemiplimab | From the date of study inclusion to the end of the treatment period. Assessed up to 2 years after inclusion | |
Secondary | Time to response and duration of response | To establish the median time to response (TTR) and duration of response (DOR) in patients with secondary angiosarcomas receiving cemiplimab. | From the date of study inclusion to the date of response or progression. Assessed up to 2 years after inclusion | |
Secondary | Progression free survival (PFS) | To assess the median progression-free survival (PFS) of patients with secondary angiosarcomas receiving cemiplimab | Counting from the date of study inclusion to the date of progressive disease or death. Assessed up to 2 years after inclusion. | |
Secondary | Overall survival (OS) | To establish the overall survival (OS) of patients with secondary angiosarcomas receiving cemiplimab | From the date of study inclusion to the date of death. If study medication is discontinued for any reason, survival follow-up takes place every 12 weeks, also assessed up to 2 years | |
Secondary | Relation between tumor characteristics and response to treatment | To investigate possible relations between response to cemiplimab and tumor characteristics (i.e. PD-L1 expression, tumour infiltrating lymphocytes, MYC status and tumour mutational burden) | 2-3 years | |
Secondary | Differences between UV associated and radiation induced secondary angiosarcomas | To assess differences in response to cemiplimab between UV associated and radiation induced secondary angiosarcomas | 2-3 years | |
Secondary | Effect on tumor tissue | To assess effects of cemiplimab on tumor tissue by comparing pre- and post-treatment biopsies | At specific timepoints tumor biopsies and liquid biopsies will be obtained. Tumor biopsies will be obtained at baseline, after 12 weeks and (voluntary) at end of treatment | |
Secondary | Adverse events and toxicity | To quantify toxicity during cemiplimab treatment | From the date of inclusion until the end of the study (by progression or at the end of the treatment period, up to 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT01441115 -
ECI301 and Radiation for Advanced or Metastatic Cancer
|
Phase 1 | |
Terminated |
NCT03257722 -
Pembrolizumab + Idelalisib for Lung Cancer Study
|
Phase 1/Phase 2 | |
Recruiting |
NCT01201096 -
Neo-adjuvant Peptide Receptor Mediated Radiotherapy With 177Lutetium in Front of Curative Intended Liver Transplantation in Patients With Hepatic Metastasis of Neuroendocrine Tumors (NEO-LEBE)
|
N/A | |
Completed |
NCT01206530 -
FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01199822 -
Study of the Safety and Pharmacokinetics of IMC-3G3 in Japanese Patients With Solid Tumors
|
Phase 1 | |
Completed |
NCT00313859 -
Phase II Study of Simvastatin Plus Irinotecan, Fluorouracil, and Leucovorin(FOLFIRI) for Metastatic CRC
|
Phase 2 | |
Completed |
NCT00377936 -
EndoTAG-1 / Gemcitabine Combination Therapy to Treat Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas
|
Phase 2 | |
Recruiting |
NCT05095207 -
Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04392479 -
TWICE-IRI: Optimization of Second-line Therapy With Aflibercept, Irinotecan (Day 1 or Day 1,3), 5-Fluorouracile and Folinic Acid in Patients With Metastatic Colorectal Cancer. A Randomized Phase III Study.
|
Phase 3 | |
Recruiting |
NCT04808466 -
Comparative Study of Lobaplatin and Paclitaxel in Advanced Gastric Cancer Patients With D2 Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy
|
Phase 2 | |
Terminated |
NCT03652493 -
Trial Evaluating the Efficacy of CARBOPLATIN in Metastatic Prostate Cancer With Gene Alterations in the Homologous Recombination Pathway
|
Phase 2 | |
Not yet recruiting |
NCT04845490 -
Comparative Study of Mitomycin and Lobaplatin in Advanced Colorectal Cancer Patients With Radical Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy
|
Phase 2 | |
Recruiting |
NCT05061082 -
Genomic Evolution of Metastasis in Gastric Cancer
|
||
Not yet recruiting |
NCT06055764 -
Role of FDG PET/CT in Patients With Metastasis of Unknown Origin
|
||
Terminated |
NCT02796729 -
CEST- Glucose Enhanced MRI for Metastatic Brain Tumours
|
Phase 2 | |
Withdrawn |
NCT01157039 -
A Trial of Glutamine to Prevent Oxaliplatin Neurotoxicity and a Pharmacokinetic Analysis of Oxaliplatin
|
Phase 2 | |
Terminated |
NCT01000948 -
A Safety Study of ZD4054 in Prior Chemotherapy Treated Patients With Metastatic Hormone-resistant Prostate Cancer
|
Phase 2 | |
Terminated |
NCT01613482 -
TraStuzumAb-Radiotherapy : Impact on the Cerebral Prevention
|
Phase 3 | |
Withdrawn |
NCT00244348 -
Hepatic Artery Infusion With Oxaliplatin
|
Phase 1/Phase 2 | |
Recruiting |
NCT04416165 -
Comparison of FDG and FAPI in Patients With Various Types of Cancer
|
N/A |